Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam RNAi IP Upheld in European Opposition Proceedings

Premium

Alnylam Pharmaceuticals said this week that its Tuschl II patent has been fully upheld by the European Patent Office in opposition proceedings.

The patent, EP 1407044, generally relates to compositions, methods, and uses of siRNAs capable of triggering an RNAi effect. Alnylam said that opponents to the patent included Merck subsidiary Sirna Therapeutics, Silence Therapeutics, Pfizer, and BASF.

"Tuschl II remains a very important and valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee," Alnylam President and COO Barry Greene said in a statement.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.